BeStock  
Stocks › Biotechnology › BRVE

Braveheart Bio BRVE

US equityMarket cap rank #2736Biotechnology
$20.39 +$1.12 (+5.81%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $20.39 0.00%
Open$19.29
Prev close$19.27
Day range$18.83 – $21.16
Volume866.7K
Market cap$1.83B
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership86.1%+86.07 pts vs. prior quarter
Institutions holding29+29 vs. prior quarter
Insider trades (recent)22 buys / 0 sellsNet buying
Short interest5.72% of floatDays to cover 19.6 · as of 30 Oct 2026
Short-sale volume share39.9%5-day average of daily volume

Short-sale volume as % of daily volume

11%24%37%50%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$2.82M (10 inflow days, 10 outflow days).

Net flow by order size, last 20 sessions

+$3.1MSuper−$274.0KBig+$116.2KMid+$641.3KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 73.7% of shares outstanding.

Largest holders

  • Forbion Capital Partners B.V.26.74%
  • OrbiMed Advisors LLC14.91%
  • Andreessen Horowitz LLC12.53%
  • Travis Murdoch10.21%
  • FMR9.29%
  • Jiangsu Hengrui Pharmaceuticals Co.,Ltd9.09%
  • Frazier Life Sciences Management, LP6.26%
  • Capital Research2.86%

By investor type

  • VC/PE Fund60.44%
  • Mutual Fund16.46%
  • Individual/Insider14.87%
  • Public Company9.10%
  • Hedge Fund0.07%
  • Private Company0.00%

Reported short interest has risen from 1.20% to 5.72% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Charles Schwab Investment Management Mutual Fund 2026/Q3 +129,720 0.2%
FMR Mutual Fund 2026/Q3 +7,585,769 9.3%
Jiangsu Hengrui Pharmaceuticals Co.,Ltd Public Company 2026/Q3 +7,420,091 9.1%
Capital Research Mutual Fund 2026/Q3 +2,334,097 2.9%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +1,131,988 1.4%
BlackRock Mutual Fund 2026/Q3 +1,007,129 1.2%
MFS Investment Management Mutual Fund 2026/Q3 +465,251 0.6%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +288,798 0.4%
UBS Asset Management Mutual Fund 2026/Q3 +229,072 0.3%
T. Rowe Price Group, Inc. Mutual Fund 2026/Q3 +182,118 0.2%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +9,111 0.0%
OrbiMed Advisors LLC VC/PE Fund 2026/Q3 +12,175,159 14.9%
BlackRock Mutual Fund 2026/Q3 +132,958 0.2%
Strategic Advisers LLC Mutual Fund 2026/Q3 +82,374 0.1%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +52,571 0.1%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
6 Aug 2026 OrbiMed Advisors LLC Private Acquisition +1,940,000 $18.00 12,175,159
6 Aug 2026 OrbiMed Advisors LLC Derivative Exercise and Retained +9,132,420 – 12,175,159
6 Aug 2026 David Lubner Independent Director Private Acquisition +55,555 $18.00 55,555
6 Aug 2026 Christopher Viehbacher Independent Chairperson Private Acquisition +83,333 $18.00 609,519
6 Aug 2026 Jiangsu Hengrui Pharmaceuticals Co.,Ltd Derivative Exercise and Retained +7,420,091 – 7,420,091
6 Aug 2026 Forbion Capital Partners B.V. Private Acquisition +3,600,000 $18.00 21,826,024
6 Aug 2026 Forbion Capital Partners B.V. Derivative Exercise and Retained +17,123,287 – 21,826,024
6 Aug 2026 Andreessen Horowitz LLC Private Acquisition +1,100,000 $18.00 10,232,420
6 Aug 2026 Andreessen Horowitz LLC Derivative Exercise and Retained +9,132,420 – 10,232,420
6 Aug 2026 Andreessen Horowitz LLC Initial Statement of Beneficial +0 – 10,232,420
6 Aug 2026 David Malek Director Private Acquisition +4,166 $18.00 1,013,297
6 Aug 2026 James Rickey Chief Financial Officer Private Acquisition +27,777 $18.00 703,575
6 Aug 2026 Michele Anderson Chief Development Officer Private Acquisition +1,111 $18.00 332,161
6 Aug 2026 Travis Murdoch Chief Executive Officer Private Acquisition +83,333 $18.00 8,333,637
4 Aug 2026 OrbiMed Advisors LLC Initial Statement of Beneficial +0 – 1,102,739
4 Aug 2026 David Lubner Independent Director Other Derivative Acquisition +60,000 $18.00 60,000
4 Aug 2026 Christopher Viehbacher Independent Chairperson Other Derivative Acquisition +30,000 $18.00 30,000
4 Aug 2026 Christopher Viehbacher Independent Chairperson Initial Statement of Beneficial +0 – 676,524
4 Aug 2026 Erez Chimovits Independent Director Other Derivative Acquisition +30,000 $18.00 30,000
4 Aug 2026 Jiangsu Hengrui Pharmaceuticals Co.,Ltd Initial Statement of Beneficial +0 – 7,420,091

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 5,153,595 5.7% 19.6
15 Oct 2026 4,905,289 5.4% 11.8
30 Sep 2026 4,128,974 4.6% 5.1
15 Sep 2026 2,461,086 2.7% 7.5
31 Aug 2026 1,397,189 2.0% 5.6
14 Aug 2026 847,773 1.2% 1.3

Discussion

No comments yet — be the first to weigh in on BRVE.

Sign in to join the discussion.

Scroll to Top